The device improves diabetes control, promotes weight loss and reduces the daily dose of insulin in diabetics.
Highlights
- Endobarrier device can improve diabetes control and promote weight loss.
- The device can be implanted through an endoscope and does not require surgery.
- When tested in diabetics, the device improved blood sugar control, weight loss, reduced liver fat and high blood pressure.
Endobarrier works in a similar way to gastric bypass surgery by preventing food from coming into contact with the first part of the small intestine, but without painful invasive surgery.
The endobarrier of a 60cm long tube-like liner or sleeve that coats the inside of the small intestine--allowing food to pass through but not to be absorbed. The device is removed after a year. The procedure aims to kick start a change in lifestyle and help people achieve better health.
In this study, Dr Robert Ryder and colleagues from City Hospital, Birmingham, UK, investigated whether this new therapy could be translated into major clinical success by creating a small NHS Endobarrier service for people having difficulties managing their type 2 diabetes and obesity.
How Effective was the Endobarrier?
The researchers report here on the outcomes of the first 31 participants (age between 28 and 62 years) to have their device removed after up to 1 year. These patients had lived with type 2 diabetes for an average of 13 years, and over half (17 patients) were taking insulin.
- All 31 participants had lost an average of 15 kgs
- They had improved blood sugar control
- Systolic blood pressure and liver fat were reduced.
- Daily insulin dose reduced from 100 to 30 units.
- Of the 17 patients who have reached 6 months post Endobarrier treatment, 11 (65%) have managed to maintain the substantial improvements in weight loss and diabetes control.
- Participants also reported considerable improvements in wellbeing, energy, and the ability to exercise.
The authors conclude: "This inaugural NHS service demonstrates Endobarrier therapy to be highly effective in patients with obesity and diabetes that has been very hard to treat, with high patient satisfaction levels, and an acceptable safety profile.”
The Endobarrier service could be a safe and cost-effective treatment for the NHS as it does not involve surgery and patients do not have to stay in hospital (so reducing the risk of infection). As endoscopy units are located all over the UK, the service could be readily disseminated, with the registry being useful for on-going monitoring worldwide."
Reference
- European Association for the Study of Diabetes (EASD) Annual Meeting.
Source-Medindia